+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bacterial Vaginosis Drugs Market by Drug Type, Drug Form, Distribution Channel, Patient Demographics, End User - Global Forecast 2025-2030- Product Image
Bacterial Vaginosis Drugs Market by Drug Type, Drug Form, Distribution Channel, Patient Demographics, End User - Global Forecast 2025-2030- Product Image
Sale

Bacterial Vaginosis Drugs Market by Drug Type, Drug Form, Distribution Channel, Patient Demographics, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6013746
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bacterial Vaginosis Drugs Market grew from USD 873.03 million in 2023 to USD 921.92 million in 2024. It is expected to continue growing at a CAGR of 5.88%, reaching USD 1.30 billion by 2030.

The scope and definition of the Bacterial Vaginosis (BV) Drugs market encompass pharmaceutical products used for treating BV, a common vaginal infection caused by an imbalance of bacteria in the vagina. These drugs primarily include antibiotics such as metronidazole, clindamycin, and tinidazole, which are used as both oral and topical formulations. The necessity of these drugs lies in their ability to alleviate symptoms, prevent complications, and reduce recurrence rates associated with BV, thus improving women's reproductive health. Application-wise, these products are utilized across hospitals, clinics, and retail pharmacies. The end-use scope primarily involves healthcare providers and patients, highlighting the importance of these drugs in maintaining gynecological health.

Market growth is propelled by factors such as increasing awareness of women's health issues, a growing prevalence of BV, and advancements in drug delivery systems. Additionally, the rising acceptance of self-medication and over-the-counter products offers lucrative growth opportunities. Innovation in drug formulations and the development of probiotics and personalized medicine approaches are emerging areas for business expansion. However, market growth is challenged by factors like antibiotic resistance, potential side effects, and stringent regulatory requirements impacting the approval of new treatments. Efforts to educate the population about proper hygiene practices can also influence market dynamics.

The latest potential opportunities arise from increasing research into non-antibiotic treatments and the development of novel therapeutics, such as microbiome-based solutions and immunomodulators, aimed at reducing BV recurrence. Collaborations between pharmaceutical companies and research institutes can bolster innovation. The market's nature demands continuous research and development to address the limitations of existing treatments and overcome challenges like patient adherence and drug resistance. Overall, firms should focus on product differentiation and strategic partnerships to capture market share, while embracing technological advancements in drug delivery and exploring untapped regional markets to achieve sustained growth.

Understanding Market Dynamics in the Bacterial Vaginosis Drugs Market

The Bacterial Vaginosis Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of bacterial vaginosis among women of reproductive age globally
    • Growing awareness and demand for effective treatments for bacterial vaginosis
    • Advancements in pharmaceutical research and development for bacterial vaginosis drugs
    • Expansion of healthcare infrastructure in developing regions supporting bacterial vaginosis treatments
  • Market Restraints
    • Limited awareness and misdiagnosis in emerging markets affecting treatment rates
    • Stigma and social taboos surrounding bacterial vaginosis impacting patient willingness to seek treatment
  • Market Opportunities
    • Development of targeted marketing strategies to raise awareness about bacterial vaginosis and available treatments among women
    • Leveraging telemedicine platforms to provide easier access to bacterial vaginosis consultations and prescriptions
    • Creating educational campaigns to destigmatize bacterial vaginosis and encourage timely medical intervention
  • Market Challenges
    • Inconsistent reimbursement policies for bacterial vaginosis treatments across different healthcare systems
    • Intense competition from generic drugs reduces market share and profitability for branded bacterial vaginosis drug manufacturers

Exploring Porter’s Five Forces for the Bacterial Vaginosis Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Bacterial Vaginosis Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Bacterial Vaginosis Drugs Market

External macro-environmental factors deeply influence the performance of the Bacterial Vaginosis Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Bacterial Vaginosis Drugs Market

The Bacterial Vaginosis Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Bacterial Vaginosis Drugs Market

The Bacterial Vaginosis Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Bacterial Vaginosis Drugs Market

The Bacterial Vaginosis Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bacterial Vaginosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Bacterial Vaginosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Over-the-counter Drugs
      • Antiseptics
      • Probiotics
    • Prescription Drugs
      • Oral Antibiotics
      • Topical Antibiotics
  • Drug Form
    • Capsules
    • Gels
      • Medicated Gels
      • Non-medicated Gels
    • Tablets
      • Effervescent Tablets
      • Extended Release Tablets
      • Immediate Release Tablets
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Patient Demographics
    • Adults
    • Elders
    • Teenagers
  • End User
    • Clinics
    • Homecare
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of bacterial vaginosis among women of reproductive age globally
5.1.1.2. Growing awareness and demand for effective treatments for bacterial vaginosis
5.1.1.3. Advancements in pharmaceutical research and development for bacterial vaginosis drugs
5.1.1.4. Expansion of healthcare infrastructure in developing regions supporting bacterial vaginosis treatments
5.1.2. Restraints
5.1.2.1. Limited awareness and misdiagnosis in emerging markets affecting treatment rates
5.1.2.2. Stigma and social taboos surrounding bacterial vaginosis impacting patient willingness to seek treatment
5.1.3. Opportunities
5.1.3.1. Development of targeted marketing strategies to raise awareness about bacterial vaginosis and available treatments among women
5.1.3.2. Leveraging telemedicine platforms to provide easier access to bacterial vaginosis consultations and prescriptions
5.1.3.3. Creating educational campaigns to destigmatize bacterial vaginosis and encourage timely medical intervention
5.1.4. Challenges
5.1.4.1. Inconsistent reimbursement policies for bacterial vaginosis treatments across different healthcare systems
5.1.4.2. Intense competition from generic drugs reduces market share and profitability for branded bacterial vaginosis drug manufacturers
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bacterial Vaginosis Drugs Market, by Drug Type
6.1. Introduction
6.2. Over-the-counter Drugs
6.2.1. Antiseptics
6.2.2. Probiotics
6.3. Prescription Drugs
6.3.1. Oral Antibiotics
6.3.2. Topical Antibiotics
7. Bacterial Vaginosis Drugs Market, by Drug Form
7.1. Introduction
7.2. Capsules
7.3. Gels
7.3.1. Medicated Gels
7.3.2. Non-medicated Gels
7.4. Tablets
7.4.1. Effervescent Tablets
7.4.2. Extended Release Tablets
7.4.3. Immediate Release Tablets
8. Bacterial Vaginosis Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Bacterial Vaginosis Drugs Market, by Patient Demographics
9.1. Introduction
9.2. Adults
9.3. Elders
9.4. Teenagers
10. Bacterial Vaginosis Drugs Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Homecare
10.4. Hospitals
11. Americas Bacterial Vaginosis Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Bacterial Vaginosis Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Bacterial Vaginosis Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BACTERIAL VAGINOSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. BACTERIAL VAGINOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. BACTERIAL VAGINOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BACTERIAL VAGINOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BACTERIAL VAGINOSIS DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TOPICAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY MEDICATED GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY NON-MEDICATED GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY EFFERVESCENT TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ELDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TEENAGERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 69. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 70. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 71. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 72. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 73. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 75. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 80. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 116. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 117. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 118. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 119. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 120. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 122. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 125. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 126. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 127. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 128. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 129. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 131. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 143. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 144. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 145. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 146. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 147. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 149. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 196. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 197. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 198. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 199. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 200. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 201. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 203. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 223. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 227. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 229. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 233. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 234. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 235. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 236. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 237. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 238. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 240. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 245. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 249. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 251. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 252. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 253. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 254. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 256. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 258. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 260. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 261. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 262. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 263. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 264. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 265. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 267. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 278. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 279. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 280. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 281. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 282. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 283. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 285. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 305. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 308. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 309. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 310. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 312. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 314. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 315. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 316. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
TABLE 317. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
TABLE 318. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 319. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 320. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 321. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 323. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
TABLE 324. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
TABLE 325. QATAR BACTERIAL VAGINOSIS DRUGS MARKET

Companies Mentioned

The leading players in the Bacterial Vaginosis Drugs market, which are profiled in this report, include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 921.92 Million
Forecasted Market Value ( USD ) by 2030 $ 1300 Million
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

2024 Global Forecast for Bacterial Vaginosis Therapeutics Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Bacterial Vaginosis Therapeutics Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Bacterial vaginosis - Pipeline Insight, 2024 - Product Image

Bacterial vaginosis - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Pregnancy and Anti-Infective Agents - Product Image

Pregnancy and Anti-Infective Agents

  • Book
From
Helicobacter Pylori Infections - Market Insight, Epidemiology And Market Forecast - 2034 - Product Image

Helicobacter Pylori Infections - Market Insight, Epidemiology And Market Forecast - 2034

  • Report
  • 180 Pages
  • Global
From
Vulvovaginal Candidiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Vulvovaginal Candidiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 137 Pages
  • Global
From

About the Bacterial Vaginosis Drug Market

Bacterial Vaginosis (BV) is a common vaginal infection caused by an imbalance of bacteria in the vagina. BV is typically treated with antibiotics, such as metronidazole, clindamycin, and tinidazole. These antibiotics are part of the Infectious Diseases Drugs market, which includes drugs used to treat a variety of bacterial, viral, and fungal infections. The Bacterial Vaginosis Drug market is a subset of the Infectious Diseases Drugs market, and is composed of antibiotics used to treat BV. These drugs are typically prescribed in the form of oral tablets, topical creams, and vaginal gels. Some companies in the Bacterial Vaginosis Drug market include Pfizer, Merck, GlaxoSmithKline, and Bayer. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.